AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02492711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's choice of chemotherapy.
Description: Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
Study NCT02492711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice of chemotherapy.
Description: Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
Study NCT01177215 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracic Surgery
Description: Wedge Resection Segmental Resection Lobectomy
Study NCT03088904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® Quadrivalent
Description: LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
Study NCT03088904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study NCT04080232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung MRI
Description: lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
Study NCT03935048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Higher protein, low glycemic load diet
Description: All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.
Study NCT03935048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Higher protein, low glycemic load diet
Description: All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.
Study NCT03935048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Higher protein, low glycemic load diet
Description: All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.
Study NCT02098538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
Study NCT03445845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
Study NCT03445845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF blocker
Description: TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.
Study NCT03445845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood specimen
Description: Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
Study NCT03445845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood specimen
Description: Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
Study NCT01527266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: sucrose beverage
Study NCT01527266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouth rinse
Description: placebo; non-caloric sweetened beverage for use as a mouth rinse
Study NCT01424163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Dose
Description: Part B
Study NCT04128033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Puncture of the RP6 point
Description: Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus.
Study NCT00814125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole (Arimidex)
Description: 1mg, orally, once daily
Study NCT00814125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Description: 20mg, orally, once daily
Study NCT00814125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nolvadex placebo
Study NCT00814125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex placebo
Study NCT03205787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trifolium pratense
Description: Red Clover extract standardized to isoflavone content.
Study NCT01215318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified vaginal tampon
Description: modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
Study NCT01215318 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: modified vaginal tampon
Description: modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
Study NCT02011022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3g MTX
Description: The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
Study NCT02011022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5g MTX
Description: The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
Study NCT02700581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low PEEP conventional ventilation
Study NCT02700581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate PEEP conventional ventilation
Study NCT02700581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low PEEP protective ventilation
Study NCT02700581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate PEEP protective ventilation
Study NCT02803515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral venous blood samples
Description: peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
Study NCT02803515 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: peripheral venous blood samples
Description: peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir (GS-9190)
Description: Tegobuvir (GS-9190) capsule, 30 mg BID
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: GS-9451 tablet, 200 mg once daily (QD)
Study NCT03921372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: Squatting for 5 minutes
Study NCT01271790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus®
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study NCT02252978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: Given PO
Study NCT02252978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT02252978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02252978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02252978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02252978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03418246 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GIC
Description: tooth colored filling
Study NCT03418246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: White filling -Biodentine
Study NCT01481246 — intervention group
Intervention type: BEHAVIORAL
Intervention: Categorization training
Description: Behavioral intervention consisting of cognitive training exercises to improve categorization performance
Study NCT01481246 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychosocial and Psychoeducational Group training
Description: Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
Study NCT01483846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
Study NCT01483846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
Study NCT02400346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunct brexpiprazole
Description: Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg.
Study NCT01312064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab and everolimus
Description: rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
Study NCT01312064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thymoglobulin and tacrolimus
Description: thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
Study NCT03785730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-restorative cavity control - NRCC group
Description: The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
Study NCT03785730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with resin composite - RCR group
Description: In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
Study NCT01181635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Standard psychotherapy for psychiatric disorders.
Study NCT04522258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber
Description: Fermentable cereal bran
Study NCT04522258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Refined cereal flour
Study NCT01654484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Description: Ophthalmic Solution, QD, 28 Days
Study NCT01654484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.0015% tafluprost
Description: Ophthalmic Solution, QD, 28 days
Study NCT01654484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 and 0.0015% tafluprost
Description: Ophthalmic Solutions, QD, 28 days
Study NCT01654484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic Solution, QD, 28 days
Study NCT00608322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled nitric oxide, 40 parts per million, for six hours.
Study NCT00608322 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham inhaled nitric oxide
Description: Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
Study NCT02153645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 240mg Amantadine HCl ER tablets
Study NCT02153645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT02153645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320mg Amantadine HCl ER tablets
Study NCT01418573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palaeolithic meal 1
Description: Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
Study NCT01418573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palaeolithic meal 2
Description: Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
Study NCT01418573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference meal
Description: Based on WHO dietary guidelines for protein, fat and carbohydrate.
Study NCT03413202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: butylphthalide(NBP)
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
Study NCT03413202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
Study NCT03275363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurocognitive battery
Description: Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span.
Study NCT03275363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
Study NCT03275363 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood tests
Description: Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
Study NCT03275363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EEG with event-related potential (ERP)
Description: 128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
Study NCT03275363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Amyloid PET CT
Description: F18 Flutametamol PET CT for selected patients
Study NCT02400346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
Study NCT03213639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg Oral Tablet
Description: once daily oral tablets
Study NCT03213639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: once daily oral tablets
Study NCT01139762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 milligrams (mg) administered orally, once daily for 26 weeks
Study NCT01139762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for 26 weeks
Study NCT01139762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride
Description: 5mg administered orally, once daily for 26 weeks
Study NCT01139762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 5mg administered orally, once daily for 26 weeks
Study NCT01675596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Description: Operable subjects
Study NCT00538239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Four 10 mg tablets taken by mouth for 5 days per week continuously
Study NCT00538239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four 10 mg tablets taken by mouth for 5 days per week continuously
Study NCT04128033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Puncture of the placebo point
Description: Puncture of a placebo point outside the meridian, with no effect
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: GS-9451 tablet, 200 mg QD
Study NCT01590563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD
Description: Insertion of a spherical IUD, one year follow-up
Study NCT01834183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study NCT01834183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir placebo
Description: placebo matching Tegobuvir (GS-9190) capsule BID
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegobuvir placebo
Description: placebo matching Tegobuvir (GS-9190) capsule BID